Aquestive Therapeutics Inc [NASDAQ: AQST] slipped around -0.34 points on Monday, while shares priced at $3.73 at the close of the session, down -8.23%. Compared to the average trading volume of 2.58M shares, AQST reached a trading volume of 7643450 in the most recent trading
Aquestive Therapeutics Inc [NASDAQ: AQST] gained 14.80% or 0.58 points to close at $4.50 with a heavy trading volume of 5775402 shares. The daily chart for AQST points out that the company has recorded 154.24% gains over the past six months. If we look at
Aquestive Therapeutics Inc [NASDAQ: AQST] surged by $0.02 during the normal trading session on while it closed the day at $4.09. The company report on April 1, 2024 at 8:00 AM that Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive. Appoints Abigail “Abbey”
Aquestive Therapeutics Inc [NASDAQ: AQST] stock went on an upward path that rose over 5.80% on Wednesday, amounting to a one-week price increase of more than 7.88%. The company report on April 1, 2024 at 8:00 AM that Aquestive Therapeutics Strengthens Board of Directors with
Aquestive Therapeutics Inc [NASDAQ: AQST] price plunged by -15.64 percent to reach at -$0.83. The company report on March 19, 2024 at 9:49 PM that Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common Stock. Leerink Partners and Piper Sandler are acting
Aquestive Therapeutics Inc [NASDAQ: AQST] loss -3.49% on the last trading session, reaching $5.25 price per share at the time. The company report on March 14, 2024 at 5:23 PM that Aquestive Therapeutics Announces Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Successfully Meets Primary and
Aquestive Therapeutics Inc [NASDAQ: AQST] closed the trading session at $5.03. The company report on March 5, 2024 at 5:05 PM that Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update. Reports full year 2023 revenue of $50.6 million and non-GAAP adjusted
© 2024, Powered by Smart TechOne
